title: Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy.
authors.affiliation: Section of Transplantation, University of Chicago, Illinois 60637, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Millis
authors.forename: D C
authors.initials: DC
authors.lastname: Cronin
authors.forename: K A
authors.initials: KA
authors.lastname: Newell
authors.forename: J B
authors.initials: JB
authors.lastname: Piper
authors.forename: E S
authors.initials: ES
authors.lastname: Woodle
authors.forename: D S
authors.initials: DS
authors.lastname: Bruce
authors.forename: H
authors.initials: H
authors.lastname: Conjeevaram
authors.forename: A L
authors.initials: AL
authors.lastname: Baker
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
mesh_terms: D003365:Costs and Cost Analysis; D006084:Graft Rejection / Q000191:economics / Q000628:therapy*; D006801:Humans; D007087:Illinois; D007166:Immunosuppressive Agents / Q000191:economics* / Q000627:therapeutic use; D007902:Length of Stay / Q000191:economics; D016853:Muromonab-CD3 / Q000191:economics* / Q000627:therapeutic use; D016559:Tacrolimus / Q000191:economics* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus